Parkinson’s disease (PD) pathology involves degeneration of nigrostriatal pathway, postulating symptoms associated with age, environment, and genetic anomalies, including nonlinear disease progression. Hallmark characteristics of PD include dopaminergic neuronal degeneration and death, which may also be exhibited by other neurological diseases, making the diagnosis of the disease intricate at early stage. Such obscure diagnosis of the disease, limited symptomatic improvements with available therapeutics, and their inability to modify the disease status instigate us to appraise the past research and formulate the colligating comprehensive insights. This review is accentuating on the role of nitric oxide, endoplasmic reticulum stress, and their association with the ubiquitin proteasome system (UPS) during PD pathology involving focus on ubiquitin ligases due to their regulatory functions. Meticulous understanding of these major disease-related pathological events and their functional alliance may render novel dimensions for better understanding of disease etiology, related mechanisms, as well as direction toward witnessing of new therapeutic targets for the management of Parkinson’s patients.
AbeyawardhaneDLLucasHR. 2019. Iron redox chemistry and implications in the Parkinson’s disease brain. Oxid Med Cell Longev2019:4609702.
2.
Alvarez-CastelaoBCastañoJG. 2011. Synphilin-1 inhibits alpha-synuclein degradation by the proteasome. Cell Mol Life Sci68(15):2643–54.
3.
AuluckPKChanHYTrojanowskiJQLeeVMBoniniNM. 2002. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science295(5556):865–8.
4.
AvrahamESzargelREyalARottREngelenderS.2005. Glycogen synthase kinase 3β modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and lewy body formation. J Biol Chem280:42877–86.
5.
BaekJHMamulaDTingstamBPereiraMHeYSvenningssonP.2019. GRP78 level is altered in the brain, but not in plasma or cerebrospinal fluid in Parkinson’s disease patients. Front Neurosci13:697.
6.
BarodiaSKPrabhakaranKKarunakaranSMishraVTapiasV.2019. Mitochondria and endoplasmic reticulum dysfunction in Parkinson’s disease [editorial]. Front Neurosci13:1171.
7.
BassoVMarchesanEPeggionCChakrabortyJvon StockumSGiacomelloM, and others. 2018. Regulation of ER-mitochondria contacts by Parkin via Mfn2. Pharmacol Res138:43–56.
8.
BealMF. 2001. Experimental models of Parkinson’s disease. Nat Rev Neurosci2(5):325–34.
9.
BertolinGJacoupyMTraverSFerrando-MiguelRSaint GeorgesTGrenierK, and others. 2015. Parkin maintains mitochondrial levels of the protective Parkinson’s disease-related enzyme 17-β hydroxysteroid dehydrogenase type 10. Cell Death Differ22:1563–76.
10.
BezardEYueZKirikDSpillantiniMG. 2013. Animal models of Parkinson’s disease: limits and relevance to neuroprotection studies. Mov Disord28(1):61–70.
11.
BradleySASteinertJR.2016. Nitric oxide-mediated posttranslational modifications: impacts at the synapse. Oxid Med Cell Longev2016:5681036.
12.
BuckTMWrightCMBrodskyJL. 2007. The activities and function of molecular chaperones in the endoplasmic reticulum. Semin Cell Dev Biol18(6):751–61.
13.
BurchellVSNelsonDESanchez-MartinezADelgado-CamprubiMIvattRMPogsonJH, and others. 2013. The Parkinson’s disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy. Nat Neurosci16:1257–65.
14.
CalìTOttoliniDVicarioMCatoniCValleseFCieriD, and others. 2019. splitGFP technology reveals dose-dependent ER-mitochondria interface modulation by α-synuclein A53T and A30P mutants. Cells8(9):1072.
15.
CasasC. 2017. GRP78 at the centre of the stage in cancer and neuroprotection. Front Neurosci11:177.
16.
ChaariA. 2019. Molecular chaperones biochemistry and role in neurodegenerative diseases. Int J Biol Macromol131:396–411.
17.
ChenCTurnbullDMReeveAK. 2019. Mitochondrial dysfunction in Parkinson’s disease—cause or consequence?Biology (Basel)8(2):38.
18.
ChenLKongXFuJXuYFangSHuaP, and others. 2009. CHIP facilitates ubiquitination of inducible nitric oxide synthase and promotes its proteasomal degradation. Cell Immunol258:38–43.
19.
ChhanganiDUpadhyayAAmanullahAJoshiVMishraA.2014. Ubiquitin ligase ITCH recruitment suppresses the aggregation and cellular toxicity of cytoplasmic misfolded proteins. Sci Rep4:5077.
20.
ChintaSJAndersenJK. 2011. Nitrosylation and nitration of mitochondrial complex I in Parkinson’s disease. Free Radic Res45(1):53–8.
21.
ChungKKThomasBLiXPletnikovaOTroncosoJCMarshL, and others. 2004. S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science. 304(5675):1328–31.
22.
CollaE. 2019. Linking the endoplasmic reticulum to Parkinson’s disease and alpha synucleinopathy. Front Neurosci13:560.
23.
CybulskyAV. 2013. The intersecting roles of endoplasmic reticulum stress, ubiquitin-proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease. Kidney Int84(1):25–33.
24.
DanielsonSRAndersenJK. 2008. Oxidative and nitrative protein modifications in Parkinson’s disease. Free Radic Biol Med. 44(10):1787–94.
25.
DantumaNPLindstenK.2010. Stressing the ubiquitin-proteasome system. Cardiovasc Res85(2):263–71.
26.
DeasEWoodNWPlun-FavreauH.2011. Mitophagy and Parkinson’s disease: the PINK1-parkin link. Biochim Biophys Acta1813(4):623–33.
27.
Del TrediciKBraakH. 2016. Sporadic Parkinson’s disease: development and distribution of α-synuclein pathology. Neuropathol Appl42(1):33–50.
28.
DickeyCAPattersonCDicksonDPetrucelliL.2007. Brain CHIP: removing the culprits in neurodegenerative disease. Trends Mol Med13(1):32–8.
29.
DimantHEbrahimi-FakhariDMcLeanPJ. 2012. Molecular chaperones and co-chaperones in Parkinson disease. Neuroscientist18(6):589–601.
30.
DingWXYinXM. 2012. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem393(7):547–64.
31.
DingXGoldbergMS. 2009. Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One4(6):e5949.
32.
EbadiMSharmaSK. 2003.Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson’s disease. Antioxid Redox Signal5(3):319–35.
33.
Ebrahimi-FakhariDSaidiLJWahlsterL.2013. Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies. Acta Neuropathol Commun. 1(1):79.
34.
EnogieruABOmoruyiSIHissDCEkpoOE. 2019. GRP78/BIP/HSPA5 as a therapeutic target in models of Parkinson’s disease: a mini review. Adv Pharmacol Sci2019:2706783.
35.
EspayAJVizcarraJAMarsiliLLangAESimonDKMerolaA, and others. 2019. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology92(7):329–37.
36.
GiassonBIDudaJEMurrayIVChenQSouzaJMHurtigHI, and others. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science290:985–9.
37.
GilksWPAbou-SleimanPMGandhiSJainSSingletonALeesAJ, and others. 2005. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet365:415–6.
38.
Gómez-SuagaPBravo-San PedroJMGonzález-PoloRAFuentesJMNiso-SantanoM.2018. ER-mitochondria signaling in Parkinson’s disease. Cell Death Dis. 9(3):337.
39.
GoodPFHsuAWernerPPerlDPOlanowCW. 1998. Protein nitration in Parkinson’s disease. J Neuropathol Exp Neurol57(4):338–42.
40.
GorbatyukMSShabashviliAChenWMeyersCSullivanLFSalganikM, and others. 2012. Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease. Mol Ther20(7):1327–37.
41.
GoswamiPGuptaSBiswasJJoshiNSwarnkarSNathC, and others. 2016a. Endoplasmic reticulum stress plays a key role in rotenone-induced apoptotic death of neurons. Mol Neurobiol53:285–98.
42.
GoswamiPGuptaSBiswasJSharmaSSinghS.2016b. Endoplasmic reticulum stress instigates the rotenone induced oxidative apoptotic neuronal death: a study in rat brain. Mol Neurobiol53:5384–400.
Guardia-LaguartaCArea-GomezERübCLiuYMagranéJBeckerD, and others. 2014. α-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci34(1):249–59.
45.
GuptaSBiswasJGuptaPSinghATiwariSMishraA, and others. 2019. Salubrinal attenuates nitric oxide mediated PERK:IRE1α: ATF-6 signaling and DNA damage in neuronal cells. Neurochem Int131:104581.
46.
GuptaSGoswamiPBiswasJJoshiNSharmaSNathC, and others. 2015. 6-Hydroxydopamine and lipopolysaccharides induced DNA damage in astrocytes: involvement of nitric oxide and mitochondria. Mutat Res Genet Toxicol Environ Mutagen778:22–36.
47.
HamAKimDWKimKHLeeSJOhKBShinJ, and others. 2013. Reynosin protects against neuronal toxicity in dopamine-induced SH-SY5Y cells and 6-hydroxydopamine-lesioned rats as models of Parkinson’s disease: reciprocal up-regulation of E6-AP and down-regulation of α-synuclein. Brain Res1524:54–61.
48.
HanJYKangMJKimKHHanPLKimHSHaJY, and others. 2015. Nitric oxide induction of parkin translocation in PTEN-induced putative kinase 1 (PINK1) deficiency: functional role of neuronal nitric oxide synthase during mitophagy. J Biol Chem290:10325–35.
49.
HaraMRThomasBCascioMBBaeBIHesterLDDawsonVL, and others. 2006. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A. 103(10):3887–9.
50.
HatakeyamaS. 2017. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem42(4):297–311.
51.
HattoriNMizunoPY. 2004. Pathogenetic mechanisms of parkin in Parkinson’s disease. Lancet. 364(9435):722–4.
52.
HunotSBoissièreFFaucheuxBBruggBMouatt-PrigentAAgidY, and others. 1996. Nitric oxide synthase and neuronal vulnerability in Parkinson’s disease. Neuroscience72(2):355–63.
53.
HutchinsJBBargerSW. 1998. Why neurons die: cell death in the nervous system. Anat Rec253(3):79–90.
54.
IravaniMMHaddonCORoseSJennerP.2006. 3-Nitrotyrosine-dependent dopaminergic neurotoxicity following direct nigral administration of a peroxynitrite but not a nitric oxide donor. Brain Res1067(1):256–62.
55.
IshiharaNEuraYMiharaK.2004. Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via GTPase activity. J Cell Sci117(Pt 26):6535–46.
Jiménez-JiménezFJAlonso-NavarroHHerreroMTGarcía-MartínEAgúndezJAG. 2016. An update on the role of nitric oxide in the neurodegenerative processes of Parkinson’s disease. Curr Med Chem23(24):2666–79.
58.
JohansenKKTorpSHFarrerMJGustavssonEKAaslyJO. 2018. A case of Parkinson’s disease with no Lewy body pathology due to a homozygous exon deletion in Parkin. Case Rep Neurol Med2018:6838965.
KakizawaSYamazawaTIinoM. 2013. Nitric oxide-induced calcium release: activationof type 1 ryanodine receptor by endogenous nitric oxide. Channels (Austin)7(1):1–5.
61.
KanekoMNomuraY.2004. Protective effects of HRD1 and 4-phenylbutyric acid against neuronal cell death [in Japanese]. Nihon Yakurigaku Zasshi124(6):391–8.
62.
KeeYHuibregtseJM. 2007. Regulation of catalytic activities of HECT ubiquitin ligases. Biochem Biophys Res Commun354(2):329–33.
63.
KitadaTAsakawaSHattoriNMatsumineHYamamuraYMinoshimaS, and others. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature92:605–8.
64.
KleinCWestenbergerA.2012. Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med2(1):a008888.
65.
KoHSBaileyRSmithWWLiuZShinJHLeeYI, and others. 2009. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A106:2897–902.
66.
KoHSUeharaTNomuraY.2002. Role of ubiquilin associated with protein-disulfide isomerase in the endoplasmic reticulum in stress-induced apoptotic cell death. J Biol Chem277:35386–92.
67.
KoumenisCNaczkiCKoritzinskyMRastaniSDiehlASonenbergN, and others. 2002. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol22(21):7405–16.
68.
KoutiLNoroozianMAkhondzadehSAbdollahiMJavadiMRFaramarziMA, and others. 2013. Nitric oxide and peroxynitrite serum levels in Parkinson’s disease: correlation of oxidative stress and the severity of the disease. Eur Rev Med Pharmacol Sci17(7):964–70.
69.
LaVoieMJCorteseGPOstaszewskiBLSchlossmacherMG. 2007. The effects of oxidative stress on parkin and other E3 ligases. J Neurochem103:2354–68.
70.
LeckerSHGoldbergALMitchWE. 2006. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol17(7):1807–19.
71.
LeeYMParkSHChungKCOhYJ. 2003. Proteomic analysis reveals upregulation of calreticulin in murine dopaminergic neuronal cells after treatment with 6-hydroxydopamine. Neurosci Lett352(1):17–20.
72.
LehtonenŠSonninenTMWojciechowskiSGoldsteinsGKoistinahoJ. 2019. Dysfunction of cellular proteostasis in Parkinson’s Disease. Front Neurosci13:457.
73.
LesageSDürrATazirMLohmannELeuteneggerALJaninS, and others. 2006. LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med354(4):422–3.
74.
LeverenzJBUmarIWangQMontineTJMcMillanPJTsuangDW, and others. 2007. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol17(2):139–45.
75.
LiJQTanLYuJT. 2014. The role of the LRRK2 gene in Parkinsonism. Mol. Neurodegener9:47.
McLeanPJKawamataHShariffSHewettJSharmaNUedaK, and others. 2002. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation.J Neurochem83(4):846–54.
78.
McLellandGLGoiranTYiWDorvalGChenCXLauingerND, and others. 2018. Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy. Elife7:e32866.
79.
MercadoGCastilloVSotoPSidhuA.2016. ER stress and Parkinson’s disease: pathological inputs that converge into the secretory pathway. Brain Res1648(Pt B):626–32.
80.
MirzaeiHSchielerJLRochetJCRegnierF.2006. Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry. Anal Chem78:2422–31.
81.
MishraADikshitPPurkayasthaSSharmaJNukinaNJanaNR. 2008. E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity. J Biol Chem283:7648–56.
82.
MulherkarSASharmaJJanaNR. 2009. The ubiquitin ligase E6-AP promotes degradation of α-synuclein. J Neurochem110:1955–64.
83.
MundTMasuda-SuzukakeMGoedertMPelhamHR. 2018. Ubiquitination of alpha-synuclein filaments by Nedd4 ligases. PLoS One13:e0200763.
84.
NaganoYYamashitaHTakahashiTKishidaSNakamuraTIsekiE, and others. 2003. Siah-1 facilitates ubiquitination and degradation of synphilin-1. J Biol Chem278(51):51504–14.
85.
NakamuraTLiptonSA. 2013. Emerging role of protein-protein transnitrosylation in cell signaling pathways. Antioxid Redox Signal18(3):239–49.
86.
NakamuraTLiptonSA. 2020. Nitric oxide-dependent protein post-translational modifications impair mitochondrial function and metabolism to contribute to neurodegenerative diseases. Antioxid Redox Signal32(12):817–33.
87.
NakamuraTPrikhodkoOAPirieENagarSAkhtarMWOhCK, and others. 2015. Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases. Neurobiol Dis84:99–108.
88.
NakamuraTTuSAkhtarMWSunicoCROkamotoSLiptonSA. 2013. Aberrant protein S-nitrosylation in neurodegenerative diseases. Neuron78(4):596–614.
89.
NakatoROhkuboYKonishiAShibataMKanekoYIwawakiT, and others. 2015. Regulation of the unfolded protein response via S-nitrosylation of sensors of endoplasmic reticulum stress. Sci Rep8(5):14812.
90.
NardinASchrepferEZivianiE.2016. Counteracting PINK/Parkin deficiency in the activation of mitophagy: a potential therapeutic intervention for Parkinson’s disease. Curr Neuropharmacol14(3):250–9.
91.
NarendraDTanakaASuenDFYouleRJ. 2009. Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy5(5):706–8.
92.
NishikawaSBrodskyJLNakatsukasaK.2005. Roles of molecular chaperones in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD). J Biochem137(5):551–5.
93.
NomuraJHosoiTKanekoMOzawaKNishiANomuraY.2016. Neuroprotection by endoplasmic reticulum stress-induced HRD1 and chaperones: possible therapeutic targets for Alzheimer’s and Parkinson’s disease. Med Sci (Basel) 4(3):14.
OhCKSultanAPlatzerJDolatabadiNSoldnerFMcClatchyDB, and others. 2017. S-Nitrosylation of PINK1 attenuates PINK1/parkin-dependent mitophagy in hiPSC-based Parkinson’s disease models. Cell Rep21:2171–82.
96.
OmuraTKanekoMOkumaYMatsubaraKNomuraY.2013. Endoplasmic reticulum stress and Parkinson’s disease: the role of HRD1 in averting apoptosis in neurodegenerative disease.Oxid Med Cell Longev. 2013:239854.
97.
OzawaKKomatsubaraATNishimuraYSawadaTKawafuneHTsumotoH, and others. 2013. S-Nitrosylation regulates mitochondrial quality control via activation of parkin. Sci Rep3:2202.
98.
OzeliusLJSenthilGSaunders-PullmanROhmannEDeligtischATagliatiM, and others. 2006. LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med354(4):424–5.
99.
PaillussonSGomez-SuagaPStoicaRLittleDGissenPDevineMJ, and others. 2017. α-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production. Acta Neuropathol134(1):129–49.
100.
ParkKWEun KimGMoralesRModaFMoreno-GonzalezIConcha-MarambioL, and others. 2017. The endoplasmic reticulum chaperone GRP78/BiP modulates prion propagation in vitro and in vivo. Sci Rep7:44723.
101.
PengHMMorishimaYJenkinsGJDunbarAYLauMPattersonC, and others. 2004. Ubiquitylation of neuronal nitric-oxide synthase by CHIP, a chaperone-dependent E3 ligase. J Biol Chem279:52970–7.
102.
PetersonBGGlaserMLRapoportTABaldridgeRD. 2019. Cycles of autoubiquitination and deubiquitination regulate the ERAD ubiquitin ligase Hrd1. Elife8:e50903.
103.
PickrellAMYouleRJ. 2015. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron85(2):257–73.
104.
Picón-PagèsPGarcia-BuendiaJMuñozFJ. 2019. Functions and dysfunctions of nitric oxide in brain. Biochim Biophys Acta Mol Basis Dis1865(8):1949–67.
105.
RadiEFormichiPBattistiCFedericoA.2014. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimers Dis42(suppl 3):S125–52.
106.
RadiR. 2018. Oxygen radicals, nitric oxide, and peroxynitrite: redox pathways in molecular medicine. Proc Natl Acad Sci U S A115(23):5839–48.
107.
RadiRCassinaAHodaraR.2002. Nitric oxide and peroxynitrite interactions with mitochondria. Biol Chem383(3–4):401–19.
108.
RathnayakeDChangTUdagamaP.2019. Selected serum cytokines and nitric oxide as potential multi marker biosignature panels for Parkinson disease of varying durations: a case-control study. BMC Neurol19(1):56.
109.
RiesLKSanderBDeolKKLetzelterMAStrieterERLorenzS.2019. Analysis of ubiquitin recognition by the HECT ligase E6AP provides insight into its linkage specificity. J Biol Chem294:6113–29.
110.
RochaEMMirandaBDSanderLH. 2018. Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiol Dis109(Pt B):249–57.
111.
RohéCFMontagnaPBreedveldGCortelliPOostraBABonifatiV.2004. Homozygous PINK1 C-terminus mutation causing early-onset parkinsonism. Ann Neurol56:427–31.
112.
RossiMAqeilanRINealeMCandiESalomoniPKnightRA, and others. 2006. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci U S A103(34):12753–8.
113.
RotinDKumarS.2009. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol10(6):398–409.
114.
SadowskiMSarcevicB.2010. Mechanisms of mono- and poly-ubiquitination: ubiquitination specificity depends on compatibility between the E2 catalytic core and amino acid residues proximal to the lysine. Cell Div5:19.
ScheffnerMStaubO.2007. HECT E3s and human disease. BMC Biochem8(S6):1–14.
117.
SharmaSKPriyaS.2017. Expanding role of molecular chaperones in regulating α-synuclein misfolding: implications in Parkinson’s disease. Cell Mol Life Sci74(4):617–29.
118.
ShinYKluckenJPattersonCHymanBTMcLeanPJ. 2005. The Co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates α-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem280:23727–34.
119.
SinghSDasTRavindranAChaturvediRKShuklaYAgarwalAK, and others. 2005. Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson’s disease. Redox Rep10:103–9.
120.
SinghSDikshitM.2007. Apoptotic neuronal death in Parkinson’s disease: involvement of nitric oxide. Brain Res Rev54(2): 233–50.
121.
SinghSKumarSDikshitM.2010. Involvement of the mitochondrial apoptotic pathway and nitric oxide synthase in dopaminergic neuronal death induced by 6-hydroxydopamine and lipopolysaccharide. Redox Rep15:115–22.
122.
SouzaJMGiassonBIChenQLeeVMIschiropoulosH.2000. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem275(24):18344–9.
123.
SunicoCRNakamuraTRockensteinEManteMAdameAChanSF, and others. 2013. S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson’s disease. Mol Neurodegener8:29.
124.
SzargelRRottREngelenderS.2008. Synphilin-1 isoforms in Parkinson’s disease: regulation by phosphorylation and ubiquitylation. Cell Mol Life Sci65:80–8.
125.
SzargelRShaniVAbd ElghaniFMekiesLNLianiERottR, and others. 2016. The PINK1, synphilin-1 and SIAH-1 complex constitutes a novel mitophagy pathway. Hum Mol Genet25:3476–90.
126.
TanjiKKamitaniTMoriFKakitaATakahashiHWakabayashiK.2010. TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson’s disease and dementia with Lewy bodies. Neurobiol Dis38:210–8.
127.
TetzlaffJEPutchaPOuteiroTFIvanovABerezovskaOHymanBT, and others. 2008. CHIP targets toxic α-synuclein oligomers for degradation. J Biol Chem283:17962–8.
128.
TieuKIschiropoulosHPrzedborskiS.2003. Nitric oxide and reactive oxygen species in Parkinson’s disease. IUBMB Life55(6):329–35.
129.
TofarisGKKimHTHourezRJungJWKimKPGoldbergAL. 2011. Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal-lysosomal pathway. Proc Natl Acad Sci U S A108:17004–9.
130.
TrubanDHouXCaulfieldTRFieselFCSpringerW.2017. PINK1, Parkin, and mitochondrial quality control: what can we learn about Parkinson’s disease pathobiology?J Parkinsons Dis7(1):13–29.
131.
TsuruAImaiYSaitoMKohnoK.2016. Novel mechanism of enhancing IRE1α-XBP1 signalling via the PERK-ATF4 pathway. Sci Rep6:24217.
132.
UpadhyayAJoshiVAmanullahAMishraRAroraNPrasadA, and others. 2017. E3 ubiquitin ligases neurobiological mechanisms: development to degeneration. Front Mol Neurosci10:151
133.
UryuKRichter-LandsbergCWelchWSunEGoldbaumONorrisEH, et al. 2006. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Am J Pathol168(3):947–61.
134.
WangHQTakahashiR.2007. Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson’s disease. Antioxid Redox Signal9(5):553–61.
135.
WangMWeySZhangYYeRLeeAS. 2009. Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid Redox Signal11(9):2307–16.
136.
WauerTSimicekMSchubertAKomanderD.2015. Mechanism of phospho-ubiquitin-induced PARKIN activation. Nature524:370–4.
137.
WenzelDMLissounovABrzovicPSKlevitRE. 2011. UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. Nature474:105–8.
138.
XilouriMBrekkORStefanisL.2016. Autophagy and alpha-synuclein: relevance to Parkinson’s disease and related synucleopathies. Mov Disord31(2):178–92.
139.
XingLFGuoHPWangDTSunLHPanSY.2016. Protective effects and mechanisms of Ndfipl on SH-SY5Y cell apoptosis in an in vitro Parkinson’s disease model. Genet Mol Res15(2).
140.
XuLRLiuXLChenJLiangY.2013. Protein disulfide isomerase interacts with tau protein and inhibits its fibrillization. PLoS One8(10):e76657.
141.
YangYXueLJXueXOuZJiangTZhangYD. 2018. MFN2 ameliorates cell apoptosis in a cellular model of Parkinson’s disease induced by rotenone. Exp Ther Med4:3680–5.
142.
YusteJETarragonECampuzanoCMRos-BernalF.2015. Implications of glial nitric oxide in neurodegenerative diseases. Front Cell Neurosci17(9):322.
143.
ZhangCSaundersAJ. 2009. An emerging role for ubiquilin 1 in regulating protein quality control system and in disease pathogenesis. Discov Med8(40):18–22.
144.
ZhangLDawsonVLDawsonTM. 2006. Role of nitric oxide in Parkinson’s disease. Pharmacol Ther109(1–2):33–41.
